Upregulation of integrin expression on monocytes in multiple sclerosis patients treated with natalizumab

Simone Dallari, Diego Franciotta, Silvia Carluccio, Lucia Signorini, Matteo Gastaldi, Elena Colombo, Roberto Bergamaschi, Francesca Elia, Sonia Villani, Pasquale Ferrante, Serena Delbue

Research output: Contribution to journalArticle

Abstract

Natalizumab is a humanized monoclonal antibody against the α4 subunit of VLA-4 integrin that is used to treat conditions such as multiple sclerosis (MS). Although its effects on lymphocytes have been widely described, little is known about its effects on monocytes. Here we described the effects of natalizumab treatment on peripheral blood monocytes from a small cohort of MS patients in terms of relative frequencies and surface integrin (CD49d and CD18) expression. We showed that natalizumab treatment altered the surface integrin expression on monocyte subsets in the peripheral compartment, suggesting a role for them as mediators of natalizumab effects.

Original languageEnglish
Article number476190
Pages (from-to)76-79
Number of pages4
JournalJournal of Neuroimmunology
Volume287
DOIs
Publication statusPublished - Oct 15 2015

    Fingerprint

Keywords

  • Monocytes
  • Multiple sclerosis
  • Natalizumab

ASJC Scopus subject areas

  • Immunology
  • Clinical Neurology
  • Immunology and Allergy
  • Neurology
  • Medicine(all)

Cite this

Dallari, S., Franciotta, D., Carluccio, S., Signorini, L., Gastaldi, M., Colombo, E., Bergamaschi, R., Elia, F., Villani, S., Ferrante, P., & Delbue, S. (2015). Upregulation of integrin expression on monocytes in multiple sclerosis patients treated with natalizumab. Journal of Neuroimmunology, 287, 76-79. [476190]. https://doi.org/10.1016/j.jneuroim.2015.08.010